Edesa Biotech, Inc. Stock News

TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea

TORONTO, ON / ACCESSWIRE / April 2, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas

TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas

TORONTO, ON / ACCESSWIRE / October 26, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr

TORONTO, ON / ACCESSWIRE / March 16, 2023 / Edesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from a Phase 2B multi-dose study of its EB01 drug cand

Amid a soft opening performance for the major equity indices, Edesa Biotech (NASDAQ: EDSA ) shot up 7% against the prior session before dipping into negative territory during the afternoon session. Th

TORONTO, ON / ACCESSWIRE / September 8, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that P

TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par N

TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Ni

Edesa is one of 4 pharmaceutical companies that received a grant from the Canadian government to develop a drug to treat COVID-19. EB01 achieved all endpoints in phase 2 clinical trial in the treatmen

Health Canada has approved to test Edesa Biotech Inc''s (NASDAQ: EDSA ) monoclonal antibody candidate, designated EB05, as COVID-19 rescue therapy for critically ill patients in the Phase 3 part of a Phase 2/3 clinical study. Approval of the company''s Phase 3 study design follows favorable Phase 2 results, demonstrating preliminary evidence of EB05''s ability to reduce mortality in Full story available on Benzinga.com

Edesa Biotech (EDSA) has received approval from Health Canada to test its monoclonal antibody candidate, designated EB05, as a rescue therapy for critically ill patients in Phase 3 part

Health Canada has approved to test Edesa Biotech Inc's (NASDAQ: EDSA) monoclonal antibody candidate, designated EB05, as COVID-19 rescue therapy for critically ill patients in the Phase 3 part of a

HC Wainwright initiated coverage on shares of Edesa Biotech (NASDAQ:EDSA) in a report published on Monday, Analyst Ratings Network reports. The brokerage issued a buy rating and a $16.00 price target on the stock. Shares of EDSA stock opened at $6.12 on Monday. Edesa Biotech has a 52 week low of $4.05 and a 52 []

Brokerages expect Edesa Biotech, Inc. (NASDAQ:EDSA) to announce earnings of ($0.37) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Edesa Biotechs earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.42). Edesa Biotech reported earnings of ($0.22) per share in the same quarter []